James Church, MD, explains new research recommending flexible sigmoidoscopy screening beginning at age 40 in average-risk individuals, based on the steadily upsurging incidence of early-onset colorectal cancer and the left-sided predominance of CRC in these patients,
Cleveland Clinic researchers have identified a specific molecular pathway that plays a key role in the link between a high-fat diet and tumor growth in the colon.
CAFs present in the rectal tumor microenvironment, when treated with radiation, increase the secretion of factors that contribute to tumor growth and cell migration. What this finding means for future treatment.
A new study is the first using multigene panel testing to examine potentially important mutations among patients with early-onset colorectal cancer. Here’s how it suggests screening should change.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Several surgeons, physicians and specialists helped design Cleveland Clinic’s new cancer building, creating an environment for efficient treatment and care for patients.
By following multiple generations of families affected by hereditary colorectal cancer syndromes, Cleveland Clinic’s Jagelman Registries are preventing cancer mortality in the third generation.
In order to make better treatment decisions for patients with rectal cancer, Cleveland Clinic researchers are exploring use of tumor gene signatures to more accurately determine lymph node status before surgery.
Cleveland Clinic researchers find a significant number of colorectal cancer patients over age 70 have Lynch syndrome. Study supports universal tumor screening across all age groups to prevent cancers in future generations.
Cleveland Clinic research uncovers the influence of cancer-associated fibroblasts and secretion of the cytokine IL-17A on stem cell renewal, chemotherapy resistance and tumor spread in colorectal cancer.
While the AJCC/CAP Regression Grading scale for rectal cancer response was based on expert consensus, the clinical relevance of the scoring had not been validated — until a recent Cleveland Clinic study.